Literature DB >> 8350760

Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes).

R Bron1, A Ortiz, J Dijkstra, T Stegmann, J Wilschut.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8350760     DOI： 10.1016/0076-6879(93)20091-g

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN： 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  9 in total

1.  Role of hemagglutinin surface density in the initial stages of influenza virus fusion: lack of evidence for cooperativity.

Authors:  S Günther-Ausborn; P Schoen; I Bartoldus; J Wilschut; T Stegmann
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Synchronized activation and refolding of influenza hemagglutinin in multimeric fusion machines.

Authors:  I Markovic; E Leikina; M Zhukovsky; J Zimmerberg; L V Chernomordik
Journal:  J Cell Biol       Date:  2001-11-26       Impact factor: 10.539

3.  Reconstruction of H3N2 influenza virus based virosome in-vitro.

Authors:  Asghar Abdoli; Hoorieh Soleimanjahi; Masoumeh Tavassoti Kheiri; Abbas Jamali; Hesam Sohani; Mohsen Abdoli; Hamid Reza Rahmatollahi
Journal:  Iran J Microbiol       Date:  2013-06

4.  Solubilization and reconstitution of vesicular stomatitis virus envelope using octylglucoside.

Authors:  M Paternostre; M Viard; O Meyer; M Ghanam; M Ollivon; R Blumenthal
Journal:  Biophys J       Date:  1997-04       Impact factor: 4.033

Review 5.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

6.  Immunogenicity and protective efficacy of virosome based vaccines against Newcastle disease.

Authors:  Rajinder Singh; Prem C Verma; Satparkash Singh
Journal:  Trop Anim Health Prod       Date:  2009-09-02       Impact factor: 1.559

7.  Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability.

Authors:  J Lederhofer; J van Lent; F Bhoelan; Z Karneva; A de Haan; J C Wilschut; T Stegmann
Journal:  Pharm Res       Date:  2018-07-03       Impact factor: 4.200

Review 8.  Virosome presents multimodel cancer therapy without viral replication.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Biomed Res Int       Date:  2013-12-04       Impact factor: 3.411

9.  A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike.

Authors:  Yme U van der Velden; Marloes Grobben; Tom G Caniels; Judith A Burger; Meliawati Poniman; Melissa Oomen; Esther Siteur-van Rijnstra; Khadija Tejjani; Denise Guerra; Ronald Kempers; Toon Stegmann; Marit J van Gils; Rogier W Sanders
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.